Camardo will also join the company's board of directors. William Lehmann, who most recently served as interim CEO, will continue to serve as president and chief operating officer.
Camardo is currently executive vice president and head of the rare disease and inflammation business units and president of US operations at Horizon Therapeutics (HZNP).
Price: 0.89, Change: +0.05, Percent Change: +6.47
|Covetrus Says it Gets Proposal From Clayton, Dubilie...|
|--April Unemployment Rate Fell in 13 US States, Payr...|
|Marvell Technology Likely to See Fiscal Q1 Beat, Opp...|
|Research Alert: CFRA Keeps Buy Opinion On Shares Of ...|
|Terreno Realty Acquires Newark Industrial Property f...|